Verition Fund Management

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 11
Average round size
info
The average size of a deal this fund participated in
$145M
Portfolio companies 10
Rounds per year 0.79
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.09
Exits 2
Key employees Soon

Areas of investment

  • Biotechnology
  • Medical
  • Life Science
  • Pharmaceutical
  • Health Care

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Verition Fund Management:
Typical Co-investors
Verition Fund Management is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Verition Fund Management:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Axel Investments Florida, St. Petersburg, United States
Basler Kantonal Bank Basel, Basel-Stadt, Switzerland
Bullion International -
CMB International's Telecom Fund. -
Etnoteam spa -
GMF Capital New York, New York, United States
Harold Grinspoon Revocable Trust -
Hasler Foundation Bern, Bern, Switzerland
Hongjian Qiye Guanli China, Shanghai
Investment Corporation of Dubai (ICD) Dubai, United Arab Emirates
Joseph Advisory Services El Paso, Texas, United States
Propulsion Ventures Canada, Montréal, Quebec
QingCi Digital China, Fujian, Xiamen
Reading Capital China, Guangdong, Shenzhen
Startupbootcamp Fintech New York New York, New York, United States
Starz Media -
Thrive Capital New York, New York, United States
Top Rank Capital Beijing, China, Fangshan
Vsun Capital China, Guangdong Province, Nanshan District

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Korro Bio

Biotechnology
Pharmaceutical
$116M05 Jan 2022 Cambridge, Massachusetts, United States

BYJU’S

E-Learning
EdTech
Education
Higher Education
Mobile
Mobile Apps
Secondary Education
Software
$351M04 Oct 2021 Bengaluru, Karnataka, India

Alebund Pharmaceuticals

Biotechnology
Life Science
Pharmaceutical
$54M13 Sep 2021 Shanghai, China

LEXEO Therapeutics

Biotechnology
Life Science
Therapeutics
$100M09 Sep 2021 New York, New York, United States

Vedanta Biosciences

Biotechnology
Business Development
Drug Discovery
Medical
$43M21 Jul 2021 Cambridge, Massachusetts, United States

Amylyx Pharmaceuticals

Biotechnology
Medical
Neuroscience
Pharmaceutical
$135M20 Jul 2021 Cambridge, Massachusetts, United States

Larimar Therapeutics

Biotechnology
Medical
Therapeutics
$95M21 May 2021 Lower Merion Township, Pennsylvania, United States

Biosplice Therapeutics

Biotechnology
Health Care
Life Science
$120M15 Apr 2021 San Diego, California, United States

GH Research

$125M12 Apr 2021 Dublin, County Dublin, Ireland
News
Amylyx Pharmaceuticals Raises $135M in Series C Financing

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

Vedanta Biosciences Raises $68M in Series D Financing

– Vedanta Biosciences, Inc. from Cambridge, MA develops new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks.
– The company closed a $68m Series D financing.
– The round was led by affiliates of Magnetar Capital with participation from Verition Fund Management, Fosun Health Capital, co-founder PureTech Health (Nasdaq: PRTC, LSE: PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors.
– The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Verition Fund Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: